Telesta Therapeutics
Pointe-claire, Quebec, Canada
About Telesta Therapeutics
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $28.6M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2015)
- Website: telestatherapeutics.com
- Phone: +1 514 697-6636
Industries & Categories
Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/telesta-therapeutics-2483518 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.